These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 23617351)

  • 1. Current opinion on optimal treatment for colorectal cancer.
    Price TJ; Segelov E; Burge M; Haller DG; Ackland SP; Tebbutt NC; Karapetis CS; Pavlakis N; Sobrero AF; Cunningham D; Shapiro JD
    Expert Rev Anticancer Ther; 2013 May; 13(5):597-611. PubMed ID: 23617351
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current Opinion on Optimal Treatment Choices in First-line Therapy for Advanced or Metastatic Colorectal Cancer: Report From the Adelaide Colorectal Tumour Group Meeting; Stockholm, Sweden; September 2008.
    Price TJ; Tebbutt NC; Karapetis CS; Segelov E; Pavlakis N; Cunningham D; Sobrero AF; Haller DG; Shapiro JD
    Clin Colorectal Cancer; 2010 Jan; 9(1):8-14. PubMed ID: 20100683
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current opinion on optimal systemic treatment for metastatic colorectal cancer: outcome of the ACTG/AGITG expert meeting ECCO 2013.
    Price TJ; Segelov E; Burge M; Haller DG; Tebbutt NC; Karapetis CS; Punt CJ; Pavlakis N; Arnold D; Gibbs P; Shapiro JD
    Expert Rev Anticancer Ther; 2014 Dec; 14(12):1477-93. PubMed ID: 25138900
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An update on treatment advances for the first-line therapy of metastatic colorectal cancer.
    Lee JJ; Chu E
    Cancer J; 2007; 13(5):276-81. PubMed ID: 17921724
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemotherapy of metastatic colorectal cancer.
    Prescrire Int; 2010 Oct; 19(109):219-24. PubMed ID: 21180382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The multidisciplinary management of gastrointestinal cancer. The integration of cytotoxics and biologicals in the treatment of metastatic colorectal cancer.
    Van Cutsem E; Geboes K
    Best Pract Res Clin Gastroenterol; 2007; 21(6):1089-108. PubMed ID: 18070705
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cetuximab plus oxaliplatin-based chemotherapy in the treatment of colorectal cancer.
    Moosmann N; Heinemann V
    Expert Rev Anticancer Ther; 2008 Mar; 8(3):319-29. PubMed ID: 18366281
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of targeted therapy with cetuximab in patients with K-ras wild-type colorectal cancer presenting with initially unresectable metastases limited to the liver in a German setting.
    Asseburg C; Frank M; Köhne CH; Hartmann JT; Griebsch I; Mohr A; Osowski U; Schulten J; Mittendorf T
    Clin Ther; 2011 Apr; 33(4):482-97. PubMed ID: 21635994
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimal treatment of metastatic colorectal cancer.
    Pessino A; Sobrero A
    Expert Rev Anticancer Ther; 2006 May; 6(5):801-12. PubMed ID: 16759170
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted therapy in colorectal cancer.
    Rajpal S; Venook AP
    Clin Adv Hematol Oncol; 2006 Feb; 4(2):124-32. PubMed ID: 16728921
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study.
    Hochster HS; Hart LL; Ramanathan RK; Childs BH; Hainsworth JD; Cohn AL; Wong L; Fehrenbacher L; Abubakr Y; Saif MW; Schwartzberg L; Hedrick E
    J Clin Oncol; 2008 Jul; 26(21):3523-9. PubMed ID: 18640933
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metastatic colorectal cancer: recent advances in its clinical management.
    Barugel ME; Vargas C; Krygier Waltier G
    Expert Rev Anticancer Ther; 2009 Dec; 9(12):1829-47. PubMed ID: 19954294
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Why do targeted agents not work in the adjuvant setting in colon cancer?
    Oyan B
    Expert Rev Anticancer Ther; 2012 Oct; 12(10):1337-45. PubMed ID: 23176621
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Third-line therapy for metastatic colorectal cancer.
    Gundgaard MG; Soerensen JB; Ehrnrooth E
    Cancer Chemother Pharmacol; 2008 Jan; 61(1):1-13. PubMed ID: 17786445
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Target Therapy in Unresectable or Metastatic Colorectal Cancer].
    Kim JH; Park SJ
    Korean J Gastroenterol; 2016 Dec; 68(6):303-311. PubMed ID: 28025473
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness analysis of bevacizumab combined with chemotherapy for the treatment of metastatic colorectal cancer in Japan.
    Shiroiwa T; Fukuda T; Tsutani K
    Clin Ther; 2007 Oct; 29(10):2256-67. PubMed ID: 18042483
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted agents for adjuvant therapy of colon cancer.
    Saif MW
    Clin Colorectal Cancer; 2006 May; 6(1):46-51. PubMed ID: 16796791
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bevacizumab and oxaliplatin-based chemotherapy in metastatic colorectal cancer.
    Beatty GL; Giantonio BJ
    Expert Rev Anticancer Ther; 2008 May; 8(5):683-8. PubMed ID: 18471041
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer.
    Tabernero J; Van Cutsem E; Díaz-Rubio E; Cervantes A; Humblet Y; André T; Van Laethem JL; Soulié P; Casado E; Verslype C; Valera JS; Tortora G; Ciardiello F; Kisker O; de Gramont A
    J Clin Oncol; 2007 Nov; 25(33):5225-32. PubMed ID: 18024868
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Phase I / II study of XELOX plus bevacizumab in Japanese patients with metastatic colorectal cancer(JO19380)].
    Sato A; Doi T; Boku N; Kato K; Komatsu Y; Yamaguchi K; Muro K; Hamamoto Y; Koizumi W; Mizunuma N; Takiuchi H
    Gan To Kagaku Ryoho; 2011 Apr; 38(4):561-9. PubMed ID: 21498982
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.